Seroconversion after Recombinant Hepatitis B Vaccination
DOI:
https://doi.org/10.3329/jom.v11i2.5461Keywords:
Hepatitis B, hepatitis B vaccine, seroconversion, BangladeshAbstract
Background: Hepatitis B virus infection is an important public health problem with significant morbidity andmortality. Recombinant hepatitis B vaccine for the prevention of hepatitis B virus infection is in practice in different
parts of the world since its availability in 1986. Government of Bangladesh has also included hepatitis B vaccine in
EPI schedule since 2005.
Materials and methods: This study was carried out to assess the seroconversion status among hepatitis B
vaccinated individuals. A total of 190 individuals including 150 vaccinated persons and 40 non-vaccinated apparently
healthy individuals were included as study population. Sources of vaccinated persons were from both EPI and non-
EPI schedule of vaccination. Age and sex matched non-vaccinated individuals served as controls for the study. All
individuals constituting the study population were screened for HBsAg by Immunochromatographic strip test and
only HBsAg-negative persons were included for estimation of their anti-HBs titer.
Results: Out of 150 vaccinated individuals, 133(88.67%) were found to have anti-HBs titer in the protective level
(>10 IU/L), while 17(11.33%) individuals had anti-HBs titer below the protective level (<10 IU/L). All non-vaccinated
controls had anti-HBs titers below the protective level. Regarding immune response developed among vaccinated
individuals, 67.78%, 23.33% and 8.89% were good-responders, hypo-responders and non-responders respectively.
Mean titer of anti-HBs was found significantly higher among recipients who received booster dose than those who
received 3 doses schedule (863.39 IU/L vs. 262.40 IU/L), indicating high antibody titer develops after booster dose.
Vaccinated group included 85 (56.67%) men and 65 (43.33%) women with protective level of anti-HBs titer found
in 85.88% male and 92.31% female individuals. There was no significant difference of anti-HBs titer between male
and female (p>0.05). Vaccinated individuals from lower socioeconomic condition have had comparatively low rate
of protective antibody than people from middle and upper classes.
Conclusion: Recombinant HB vaccine induces good level of protective immunity among vaccinated persons.
Keywords: Hepatitis B; hepatitis B vaccine; seroconversion; Bangladesh
DOI: 10.3329/jom.v11i2.5461
J MEDICINE 2010; 11 : 143-150
Downloads
Download data is not yet available.
Abstract
152
152
PDF
90
90
Downloads
How to Cite
Guho, A., Ahad, M. abdul, Salam, M. A., Alim, M. A., Haque, A. E., & Islam, Q. T. (2010). Seroconversion after Recombinant Hepatitis B Vaccination. Journal of Medicine, 11(2), 143–150. https://doi.org/10.3329/jom.v11i2.5461
Issue
Section
Original Articles
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).